Patient Preference Between Cabazitaxel and Docetaxel for First-Line Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
Eur Urol 2021 Nov 14;[EPub Ahead of Print], G Baciarello, R Delva, G Gravis, Y Tazi, P Beuzeboc, M Gross-Goupil, E Bompas, F Joly, C Greilsamer, TNT Hon, P Barthelemy, S Culine, JF Berdah, M Deblock, R Ratta, A Flechon, C Cheneau, A Maillard, G Martineau, I Borget, K FizaziFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.